You are here

Article Text

Article menu
Download PDFPDF
Letter
Ustekinumab for the treatment of refractory giant cell arteritis
  1. Richard Conway1,2,
  2. Lorraine O'Neill1,
  3. Eileen O'Flynn1,
  4. Phil Gallagher1,
  5. Geraldine M McCarthy3,
  6. Conor C Murphy4,
  7. Douglas J Veale1,
  8. Ursula Fearon1,
  9. Eamonn S Molloy1
  1. 1 Department of Rheumatology, Centre for Arthritis and Rheumatic Diseases, St Vincent's University Hospital, Dublin Academic Medical Centre, Dublin 4, Ireland
  2. 2 CARD Newman Research Fellow, University College Dublin, Dublin 4, Ireland
  3. 3 Mater Misericordiae University Hospital, Dublin Academic Medical Centre, Dublin 7, Ireland
  4. 4 RCSI Department of Ophthalmology, Royal College of Surgeons of Ireland, Royal Victoria Eye and Ear Hospital, Dublin 2, Ireland
  1. Correspondence to Dr Richard Conway, Department of Rheumatology, Centre for Arthritis and Rheumatic Diseases, St Vincent's University Hospital, Dublin Academic Medical Centre, Elm Park, Dublin 4, D04 T6F4, Ireland; drrichardconway{at}gmail.com

https://doi.org/10.1136/annrheumdis-2016-209351

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Giant cell arteritis (GCA) is the most common form of systemic vasculitis.1 Glucocorticoids are the mainstay of therapy, required in high doses for prolonged periods, with consequent serious complications in 86% of patients.2 There is a critical unmet need for a proven safe and effective immunosuppressive therapy in GCA, as agents such as methotrexate and infliximab have shown disappointing results in GCA.3 ,4 Interleukins 12 (IL-12) and 23 (IL-23) are implicated in Th1 and Th17 responses, respectively, both inflammatory pathways relevant to GCA pathogenesis.5 ,6 A recent case series reported the use of ustekinumab in three patients with Takayasu arteritis.7 The aim of this study was to evaluate the glucocorticoid-sparing efficacy of ustekinumab, an IL-12/IL-23-blocking monoclonal antibody, in patients with refractory GCA.

    Patients with GCA attending our centre are enrolled in a prospective registry and managed according to standardised …

    View Full Text